• 15 Jul 2015

    Trends in Psoriasis Payer Management

    Larisa Vulakh, Senior Analyst, Zitter Health Insights

    The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. The newest entrant into the psoriasis market, Novartis’ Cosentyx, was approved in January 2015. By targeting IL-7, Cosentyx’s unique mechanism of […]

    read more
  • 10 Jul 2015

    July 2015 Greater Data Granularity in Covered Lives

    ZHI, Zitter Health Insights

    As a part of Zitter Health Insights’ ongoing commitment to continuously improving its products, ZHI has expanded the covered lives granularity and is including more timely updates for greater accuracy. This lives enhancement also includes more detailed PBM information and is a value added service to our well regarded and widely accepted Policy & Access Tracking Tool.

    read more
  • 24 Jun 2015

    Drivers of Rheumatoid Arthritis Prescription Abandonment

    Jennifer Rawding, Senior Analyst, Zitter Health Insights

    Patient prescription abandonment and medication non-adherence is a major market concern, with estimates of up to one-third of written prescriptions not being filled and projected costs of $290 billion each year from non-adherence1. While more traditional research focuses on prescription fill rates, the Abandonment Insight Monitor dives more deeply into which factors drive patient decisions to […]

    read more
  • 01 Jun 2015

    Biosimilars in Rheumatoid Arthritis: What to Expect?

    Dinesh K. Kabaleeswaran, Analyst, Zitter Health Insights

    Rheumatoid arthritis (RA) has traditionally been one of the more competitive markets for new entrants with the TNF-alpha inhibitor class of drugs enjoying a good percentage of the market share. By effectively inhibiting the response to tumor necrosis factor (TNF), a cytokine released during the inflammatory response, Amgen’s Enbrel and Abbvie’s Humira have continued to […]

    read more
  • 11 May 2015

    Impact of the entrance of PCSK9i to the hypercholesterolemia market in Q3 2015

    Nadia Krasner, PhD, Senior Analyst, Zitter Health Insights

    Amgen and Regeneron/Sanofi are in a heated race to launch their respective PCSK9 inhibitors (PCSK9i), Repatha and Praluent, late this summer. These new drugs are highly efficacious, reducing LDL cholesterol levels up to an additional 60%, and tout a low instance of adverse events. Although these treatments could have a significant impact, filling the unmet […]

    read more